Literature DB >> 26358253

BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.

George S Karagiannis1, Hara Afaloniati2, Elisavet Karamanavi3,4, Theofilos Poutahidis3, Katerina Angelopoulou5.   

Abstract

The suppression of the bone morphogenetic protein (BMP) signaling pathway has been recently shown to promote adenoma-to-carcinoma transition in sporadic colon cancer. However, its role in the evolution of early preneoplastic changes to neoplasia remains elusive. In the present study, we aimed to investigate the gene expression levels of multiple extracellular BMP family constituents, including BMP ligands/receptors and inhibitors, during the early stages of inflammation-associated colon carcinogenesis. For that, we used the recently developed urokinase-type plasminogen activator (uPA)-deficient mouse model of colonic polypoidogenesis, in which adenomatous polyps arise several months after the induction of dextran sodium sulfate (DSS) colitis. In DSS-treated wild-type mice, the preneoplastic lesions which did not eventually evolve to adenomas resided in a colitic microenvironment characterized by a balanced upregulation of both BMP ligands, i.e., Bmp4/7 and BMP inhibitors, such as chordin, noggin, and gremlin-1. In the uPA-deficient tumor-promoting inflammatory microenvironment, however, there was a clear evidence for BMP pathway suppression. By contrast to DSS-treated wild-type controls, the inflammation-associated Bmp4 upregulation was abolished, and the BMP signaling suppression was further enhanced by a particularly high increase of gremlin-1 expression. These findings propose that BMP pathway suppression in colon cancer could be associated with very early stages of the preneoplasia-to-neoplasia sequence of events.

Entities:  

Keywords:  BMP; Colitis; Colorectal cancer; GREM1; Mouse; uPA

Mesh:

Substances:

Year:  2015        PMID: 26358253     DOI: 10.1007/s13277-015-3988-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells.

Authors:  Haiyun Deng; Ryouji Makizumi; T S Ravikumar; Huali Dong; Wancai Yang; Weng-Lang Yang
Journal:  Exp Cell Res       Date:  2007-01-10       Impact factor: 3.905

2.  Bone morphogenetic proteins (BMPs): from morphogens to metabologens.

Authors:  A Hari Reddi; Anand Reddi
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-08       Impact factor: 7.638

Review 3.  Recent advances in BMP receptor signaling.

Authors:  Christina Sieber; Jessica Kopf; Christian Hiepen; Petra Knaus
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-07       Impact factor: 7.638

Review 4.  Bone morphogenetic proteins and their antagonists: current and emerging clinical uses.

Authors:  Imran H A Ali; Derek P Brazil
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 5.  Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue.

Authors:  George S Karagiannis; Theofilos Poutahidis; Susan E Erdman; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Cancer Res       Date:  2012-09-28       Impact factor: 5.852

Review 6.  The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation.

Authors:  Mario Del Rosso; Francesca Margheri; Simona Serratì; Anastasia Chillà; Anna Laurenzana; Gabriella Fibbi
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1.

Authors:  Yucheng Yao; Amina F Zebboudj; Esther Shao; Martin Perez; Kristina Boström
Journal:  J Biol Chem       Date:  2006-09-01       Impact factor: 5.157

8.  Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis.

Authors:  J R Howe; J L Bair; M G Sayed; M E Anderson; F A Mitros; G M Petersen; V E Velculescu; G Traverso; B Vogelstein
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

Review 9.  Signaling mechanisms of the epithelial-mesenchymal transition.

Authors:  David M Gonzalez; Damian Medici
Journal:  Sci Signal       Date:  2014-09-23       Impact factor: 8.192

10.  Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis.

Authors:  George S Karagiannis; Constantina Petraki; Ioannis Prassas; Punit Saraon; Natasha Musrap; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Oncotarget       Date:  2012-03
View more
  10 in total

1.  Identification of hub genes and pathways in colitis-associated colon cancer by integrated bioinformatic analysis.

Authors:  Yongming Huang; Xiaoyuan Zhang; Yansen Li; Jie Yao
Journal:  BMC Genom Data       Date:  2022-06-22

2.  An In Vitro Evaluation of Selenium Nanoparticles on Osteoblastic Differentiation and Antimicrobial Properties against Porphyromonas gingivalis.

Authors:  Jason Hou; Yukihiko Tamura; Hsin-Ying Lu; Yuta Takahashi; Shohei Kasugai; Hidemi Nakata; Shinji Kuroda
Journal:  Nanomaterials (Basel)       Date:  2022-05-28       Impact factor: 5.719

3.  Inflammation-induced colon cancer in uPA-deficient mice is associated with a deregulated expression of Notch signaling pathway components.

Authors:  Hara Afaloniati; George S Karagiannis; Emmanouel Karavanis; Theophano A Psarra; Anastasios Karampatzakis-Kouritas; Theofilos Poutahidis; Katerina Angelopoulou
Journal:  Mol Cell Biochem       Date:  2019-11-22       Impact factor: 3.396

4.  Therapeutic strategies against cancer stem cells in human colorectal cancer.

Authors:  Magdalena Szaryńska; Agata Olejniczak; Jarosław Kobiela; Piotr Spychalski; Zbigniew Kmieć
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

5.  Identification of Monotonically Differentially Expressed Genes across Pathologic Stages for Cancers.

Authors:  Suyan Tian; Chi Wang; Mingbo Tang; Jialin Li; Wei Liu
Journal:  J Oncol       Date:  2020-11-12       Impact factor: 4.375

6.  Identification of liver-derived bone morphogenetic protein (BMP)-9 as a potential new candidate for treatment of colorectal cancer.

Authors:  Chen Cai; Timo Itzel; Haristi Gaitantzi; Carolina de la Torre; Emrullah Birgin; Johannes Betge; Norbert Gretz; Andreas Teufel; Nuh N Rahbari; Matthias P Ebert; Katja Breitkopf-Heinlein
Journal:  J Cell Mol Med       Date:  2021-11-28       Impact factor: 5.310

Review 7.  Insights into the Role of Gremlin-1, a Bone Morphogenic Protein Antagonist, in Cancer Initiation and Progression.

Authors:  Noha Mousaad Elemam; Abdullah Imadeddin Malek; Esraa Elaraby Mahmoud; Waseem El-Huneidi; Iman M Talaat
Journal:  Biomedicines       Date:  2022-01-28

8.  Gremlin-1 Promotes Colorectal Cancer Cell Metastasis by Activating ATF6 and Inhibiting ATF4 Pathways.

Authors:  Ruohan Li; Huaixiang Zhou; Mingzhe Li; Qiuyan Mai; Zhang Fu; Youheng Jiang; Changxue Li; Yunfei Gao; Yunping Fan; Kaiming Wu; Clive Da Costa; Xia Sheng; Yulong He; Ningning Li
Journal:  Cells       Date:  2022-07-07       Impact factor: 7.666

Review 9.  Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways.

Authors:  Mao-Lin Wan; Yu Wang; Zhi Zeng; Bo Deng; Bi-Sheng Zhu; Ting Cao; Yu-Kun Li; Jiao Xiao; Qi Han; Qing Wu
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

10.  Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma.

Authors:  Zhengchun Wu; Rushi Liu; Xiongying Miao; Daiqiang Li; Qiong Zou; Yuan Yuan; Zhulin Yang
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.